Our leadership team, including recognized physician experts and researchers, is at the forefront of shaping new standards of cancer care based upon the latest research. Patients are at the heart of everything we do. Sarah Cannon offers integrated cancer services, providing patients with cutting-edge treatments and upholding the highest quality care for patients from diagnosis through survivorship.
Johanna C. Bendell, MD
Director, GI Cancer Research Program; Associate Director, Drug Development Program
Dr. Bendell joined Sarah Cannon in 2008 and serves as the director of the GI cancer research program and associate director of the drug development program. She leads the clinical trial menu for GI Cancers for Sarah Cannon Research Institute, as well as designs trials for GI cancers. She also works in early drug development to help guide first-in-man agents to proof of concept studies.
Dr. Bendell received her undergraduate and medical degrees from the University of Chicago in 1994 and 1998, respectively. She completed her internship and residency in the Department of Internal Medicine at Brigham and Women's Hospital in Boston, as well as a fellowship in adult oncology at Boston's Dana-Farber Cancer Institute. She is board certified in medical oncology. Additionally, she is an associate with Tennessee Oncology, PLLC.